MicroRNA-218 Regulates the Chemo-sensitivity of Cervical Cancer Cells Through Targeting Survivin

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Aug 3

PMID 31372052

Citations 12

Authors

Minmin Yu

Baozhen Xu

Hui Yang

Songlin Xue

Rong Zhang

Hongmei Zhang

Xiaoyan Ying

Zhiqin Dai

Affiliations

Soon will be listed here.

Abstract

Cervical cancer is one of the most lethal malignancies among women in the world. Every year about 311,365 women die because of cervical cancer. Chemo-resistance is the main reason of the lethal malignancies, and the mechanism of chemo-resistance in cervical cancer still remains largely elusive. Previous studies reported that microRNAs played important biological roles in the chemo-resistance in many types of cancers, in the present study we tried to investigate the biological roles of microRNA-218 in chemo-resistance in cervical cancer cells. Real-time PCR results indicated microRNA-218 was downregulated in cisplatin-resistant HeLa/DDP and SiHa/DDP cells compared with the mock HeLa and SiHa cells. CCK-8 assay results showed upregulation of microRNA-218 enhanced the cisplatin sensitivity of cervical cancer cells; while downregulation of microRNA-218 decreased the cisplatin sensitivity of cervical cancer cells. Dual-luciferase assay indicated survivin was a direct target of microRNA-218. Western blotting and PCR results indicated the expression of survivin in HeLa/DDP and SiHa/DDP cells was significantly increased compared with HeLa and SiHa cells. Further study indicated induction of microRNA-218 decreased the expression of survivin while inhibition of microRNA-218 increased the expression of survivin in cervical cancer cells. Cell apoptosis results indicated induction of microRNA-218 induced the cell apoptosis in cervical cancer cells. Our data revealed microRNA-218 enhanced the cisplatin sensitivity in cervical cancer cells through regulation of cell growth and cell apoptosis, which could potentially benefit to the cervical cancer treatment in the future.

Citing Articles

Prognostic and clinicopathological significance of survivin in gynecological cancer.

Chuwa A, Mvunta D Oncol Rev. 2024; 18:1444008.

PMID: 39687493 PMC: 11646728. DOI: 10.3389/or.2024.1444008.

Relationship Between Expression of microRNA and Chemotherapy Resistance in Cervical Carcinoma.

Chao-Hui H, Jing L, Xue C, Ting-Shi W, Chong L Appl Biochem Biotechnol. 2022; 195(3):1928-1946.

PMID: 36401723 DOI: 10.1007/s12010-022-04227-6.

Diagnostic value of colposcopy in patients with cytology-negative and HR-HPV-positive cervical lesions.

Liu Y, Liao J, Yi X, Pan Z, Pan J, Sun C Arch Gynecol Obstet. 2022; 306(4):1161-1169.

PMID: 35320389 DOI: 10.1007/s00404-022-06415-5.

MicroRNA-92a-3p Enhances Cisplatin Resistance by Regulating Krüppel-Like Factor 4-Mediated Cell Apoptosis and Epithelial-to-Mesenchymal Transition in Cervical Cancer.

Yang J, Hai J, Dong X, Zhang M, Duan S Front Pharmacol. 2022; 12:783213.

PMID: 35095494 PMC: 8795743. DOI: 10.3389/fphar.2021.783213.

MiRNA-218 inhibits cell proliferation, migration and invasion by targeting Runt-related transcription factor 2 (Runx2) in human osteosarcoma cells.

Guo Q, Ma J, Wu J Regen Ther. 2022; 18:508-515.

PMID: 34977284 PMC: 8668442. DOI: 10.1016/j.reth.2021.11.003.

References

Thomas G . Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. N Engl J Med. 1999; 340(15):1198-200. DOI: 10.1056/NEJM199904153401509. View

Martin-Martinez A, Molano F, LLoret M, Falcon-Vizcaino O, Garcia-Hernandez J . Concurrent chemotherapy and radiotherapy for cervical cancer. Eur J Gynaecol Oncol. 2003; 24(2):160-2. View

Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I . HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003; 22(11):2729-40. PMC: 156760. DOI: 10.1093/emboj/cdg263. View

Lukka H, Johnston M . Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer: a meta-analysis. Clin Oncol (R Coll Radiol). 2004; 16(2):160-1. DOI: 10.1016/j.clon.2004.01.002. View

Ellenson L, Wu T . Focus on endometrial and cervical cancer. Cancer Cell. 2004; 5(6):533-8. DOI: 10.1016/j.ccr.2004.05.029. View

Brewer C, Blessing J, Nagourney R, McMeekin D, Lele S, Zweizig S . Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005; 100(2):385-8. DOI: 10.1016/j.ygyno.2005.09.009. View

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

Kostova I . Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov. 2008; 1(1):1-22. DOI: 10.2174/157489206775246458. View

Li J, Huang H, Sun L, Yang M, Pan C, Chen W . MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 2009; 15(12):3998-4008. DOI: 10.1158/1078-0432.CCR-08-3053. View

10.

Olszewski U, Hamilton G . A better platinum-based anticancer drug yet to come?. Anticancer Agents Med Chem. 2010; 10(4):293-301. DOI: 10.2174/187152010791162306. View

11.

Yu Z, Zhong L, Ji T, Zhang P, Chen W, Zhang C . MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol. 2010; 46(4):317-22. DOI: 10.1016/j.oraloncology.2010.02.002. View

12.

Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S . MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010; 6(3):e1000879. PMC: 2837402. DOI: 10.1371/journal.pgen.1000879. View

13.

Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H . miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer. 2010; 103(6):877-84. PMC: 2966617. DOI: 10.1038/sj.bjc.6605811. View

14.

Glud M, Rossing M, Hother C, Holst L, Hastrup N, Nielsen F . Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res. 2010; 20(6):479-84. DOI: 10.1097/CMR.0b013e32833e32a1. View

15.

Wu D, Cheng Y, Wang J, Chen C, Lee H . Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res. 2010; 70(24):10392-401. DOI: 10.1158/0008-5472.CAN-10-2341. View

16.

Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K . The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 2011; 104(5):808-18. PMC: 3048214. DOI: 10.1038/bjc.2011.23. View

17.

Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y . miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2011; 127(12):2804-14. DOI: 10.1002/ijc.25284. View

18.

Alajez N, Lenarduzzi M, Ito E, Hui A, Shi W, Bruce J . MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011; 71(6):2381-91. DOI: 10.1158/0008-5472.CAN-10-2754. View

19.

Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H . miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol. 2011; 39(1):13-21. DOI: 10.3892/ijo.2011.1012. View

20.

Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M . MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2011; 31(4):432-45. DOI: 10.1038/onc.2011.263. View